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TABLE Lod scores (Z) for neurofibromatosis and the marker loci.
Marker/chromosomal Recombination fraction (H) -(0 M=bf)
location
0-001 00- 0-10 0-20 0-30 0-40
C3/19pter--*q13-2 -3-740 -1-441 -0-892 -0-400 -0-166 -0-046
ApoC2/19cen--ql3 -2-129 -0-430 -0-153 0-041 0-061 0-023
pBAM34(Dl9S6)/19q13-3 -7-300 -2-770 -1-753 -0-777 -0-318 -0-102
LDR111/17 -10-158 -4-671 -3-013 -1-376 -0-602 -2-028
LDR92/17 -7-591 -1-817 -0-713 0-107 0-273 0-167
HUAP(APRT)/16q22 -8-964 -3-581 -2-450 -1-346 -0-698 -0-258
pE40- I(DI lS21)/ 1 p3- 15 -8-582 -2-094 -1-068 -0-243 0-040 0-094
Hp(Hp2a and Hp serum)/16q22-1 -2-424 -0-417 0-054 0-399 0-370 0-195
Discussion
These results represent our initial attempt to localise
the gene for NF. At present, the data are inconclu-
sive. We will continue to screen this pedigree and
our other large multi-generation NF families for
linkage until a successful linkage is found.
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SUMMARY Linkage relationships of the gene
for peripheral neurofibromatosis (NF) were
assessed in a large American Caucasian pedi-
gree using two DNA markers located on
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chromosome 8. Linkage to the thyroglobulin
locus, located at 8q24, was excluded (lod
<-2-0) to 21 cM. Data obtained for the tissue
plasminogen activator locus, located at 8p12,
excluded linkage to 4 cM. These results ex-
clude between 20 to 30% of chromosome 8 as a
possible map location for the NF gene in this
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family. Comparison of the two DNA markers
excluded their linkage to 0O5 cM.
As documented in the accompanying papers, the
exclusion map for the location of the gene respon-
sible for peripheral neurofibromatosis is becoming
substantial. We have been investigating the possibil-
ity that this gene is located on chromosome 8, a
chromosome for which until recently very few
markers were available. This chromosome is of
interest for two reasons. (1) It is the site of two
known oncogenes, the mos and myc proto-
oncogenes. (2) NF has recently been observed in
association with a potentially de novo complex
chromosomal rearrangement (Kittur, Valle, and
Kazazian, personal communication) involving
chromosomes lq, 8q, and 15q with two breakpoints
on 8q. The affected subject, a 13 year old female,
exhibits symptoms of NF including multiple cafe au
lait spots, macrocephaly, and thoracolumbar scoliosis.
While the presence of features of NF could repre-
sent the simultaneous but unrelated occurrence of
two different genetic conditions in the child, it is also
possible that one of the breakpoints involved in the
rearrangement has interrupted or activated a gene
which is responsible for NF. In a possibly related
observation, Palmer et all have recently reported a
child with trisomy 8 mosaicism who developed
features consistent with NF as well as chronic
granulocytic leukaemia. Although this evidence is
highly circumstantial, it can be regarded as useful in
that it suggests possible chromosomes on which to
seek linkage.
We are also concerned about the possibility of
locus heterogeneity in NF. Therefore, we have
chosen to do our linkage analyses using a very large
American Caucasian pedigree segregating for NF,
in order to avoid the risk of failing to detect linkage
due to pooling families that have different loci
responsible for the NF disease phenotype.
Methods
The pedigree segregating for NF used in this study
and the criteria for diagnosis of NF are described
elsewhere. 2
DNA was isolated either directly from venous
blood or from EBV transformed B lymphocyte
cultures.2 Restriction endonuclease digestions, agar-
ose electrophoresis, and Southern blotting were
carried out using standard methods.3 Linkage to NF
was tested for two DNA markers located on
chromosome 8 that exhibit restriction fragment
length polymorphisms. We used a genomic DNA
clone containing part of the thyroglobulin (TG)
locus (pCHT16/8-0) that has been mapped to 8q244
to detect a two allele TaqI polymorphism.4 We also
used a cDNA clone (pTPA) containing the entire
coding region of the tissue plasminogen activator
(PLAT) locus. This gene has been mapped to 8p125
and detects a two allele EcoRI polymorphism.6
Since both DNA markers used here are located
on chromosome 8, we also assessed linkage between
these marker loci in order to begin to develop a
linkage map for this chromosome. Adult subjects of
uncertain NF diagnosis were not included in the NF
linkage analysis. Prepubescents were also excluded
from the NF linkage analysis, because of the age
dependent penetrance of this disease.7 Both of these
groups were used in the analysis of linkage between
the two DNA markers. Therefore, for evaluating
linkage to NF, we used 45 subjects (25 affected) with
known TG genotypes and 36 subjects (19 affected)
with known PLAT genotypes. Genotypes were
determined for 44 subjects for both TG and PLAT
irrespective of NF status, and these were used for
assessing linkage between these DNA markers.
Linkage to NF was assessed by the method of lod
scores8 using the programme LIPED.9 The following
allele frequencies were used in our analyses: 0-8 for
the 5-2 kb TG allele4; 0-5 for both PLAT alleles6;
and 0-0003 for NF.7 We assumed penetrance of 95%
for NF for post-pubescent subjects. Equal recom-
bination fractions were assumed for males and
females. An estimate of the number of potentially
informative meioses within this complex pedigree is
discussed elsewhere.2 Customarily, a lod score less
than -2-0 is considered sufficient to exclude linkage
between loci.8
Results
Lod scores estimating linkage between each of the
DNA markers and NF and between the two DNA
markers are presented in the table. Linkage to NF
can be excluded up to a recombination fraction of
0.21 for the TG locus and 0 04 for the PLAT locus.
Additional analyses indicated that inclusion of
apparently unaffected prepubescent subjects and
the assumption of 100% penetrance for NF among
adults had only small effects on lod scores.
TABLE Lod scores testing linkage of chromosome 8 DNA
markers to the NF locus and each other.
Loci 6




TG - -5 93 -4-35 -2-23 -1-01 -0-31
PLAT -10-32 -1-88 -0-88 0-07 0-16 0-13
PLAT -- -0-69 -0-23 0-12 0-17 (-()9
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Linkage of the TG and PLAT loci to each other
can be excluded up to a recombination fraction of
0-005. These relatively small recombination frac-
tions are converted into essentially equal genetic
map distances by applying any of the commonly
used mapping functions that allow for interference.
The smaller range of exclusion associated with both
linkage tests involving the PLAT marker is attribut-
able to the smaller sample of subjects at this locus
and the occurrence of fewer informative heterozy-
gotes among those subjects sampled.
Discussion
The results of this linkage study exclude a significant
portion of chromosome 8 as the potential site of the
NF locus. Since the entire human genoine consists of
about 3300 cM of map distance,t and since chromo-
some 8 is an average size chromosome, we estimate
that chromosome 8 spans about 150 cM of map
distance. If the TG locus is actually located very
close to the telomere in 8q24, we can only exclude
linkage to NF in one direction. However, if it is
located more proximally, our data would permit
exclusion of 21 cM on either side of this locus. Since
the PLAT marker excludes linkage in both direc-
tions, the combination of these DNA markers
excludes between 29 to 50 cM (20 to 30%) of
chromosome 8. The application of additional
chromosome 8 markers to this NF pedigree is
therefore necessary to exclude this chromosome
fully as a potential location for the NF gene.
S R Diehl et al
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Further exclusion data for the Von Recklinghausen
neurofibromatosis gene: a genetic linkage study of 19 polymorphic
markers
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SUMMARY Linkage analysis on a panel of 15
Von Recklinghausen neurofibromatosis
(VRNF) families with 19 polymorphic markers
was carried out using the computer programme
M-Link. Our findings have excluded VRNF
from a significant proportion of the genome.
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Von Recklinghausen neurofibromatosis (VRNF) is
one of the commonest autosomal dominant dis-
orders in man with a prevalence of at least
20/100 000' of the population. The mapping of the
VRNF gene will be an important step towards our
eventual understanding of the pathogenesis of the
disease and a closely linked marker would be
immediately applicable in prenatal diagnosis where
appropriate.
